Document Detail

Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.
MedLine Citation:
PMID:  15661216     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Although paclitaxel and carboplatin therapy (TC) is an established effective standard regimen for patients with ovarian cancer, both treatment delay for hematologic toxicity and discontinuation of treatment due to neurotoxicity have occasionally been reported. To achieve therapeutic density, we evaluated the usefulness of weekly low-dose TC therapy (WTC) in patients with platinum-sensitive (median PFI was 11.4 +/- 2.7 months) recurrent epithelial ovarian cancer. METHODS: A total of 25 patients were treated with paclitaxel at 60 mg/m(2) and carboplatin at AUC = 2 using 3 weekly courses with a 1-week break schedule. Eighteen patients had assessable tumors for response, and the other seven patients were evaluated by CA-125-based response. All of the patients were assessable for toxicity. RESULTS: The overall response rate (OR) based on WHO criteria was 84.2% (95% CI; 0.65-0.98), including nine complete responses (CR); OR based on CA-125 was 85.7% (95% CI; 0.42-0.99), including 3 CR. The total response rate was 88.0% (95% C.I.; 0.68-0.97). The median progression-free survival of the patients was 13.5 months during the mean follow-up period of 21.9 +/- 9.2 months. No patients had grade 1 or higher thrombocytopenia, and although 44% of the patients developed neurotoxicity, all cases remained grade 1. Treatment delay of over 7 days due to toxicity was observed in only two patients (16.0%) and in six cycles (1.3%) in a total of 451 cycles. CONCLUSION: WTC combination, as used in this study, produced a high response rate with acceptable toxicity, and the optimal combination in a weekly regimen remains to be determined.
Yoh Watanabe; Hidekatsu Nakai; Haruhiko Ueda; Hiroshi Hoshiai
Related Documents :
9007136 - Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in...
17634546 - A phase ib and pharmacokinetic trial of patupilone combined with carboplatin in patient...
2177346 - Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a cancer and leu...
10193946 - High dose chemotherapy with autologous stem cell support in the treatment of patients w...
19153116 - Efficacy of folfiri-3 (irinotecan d1,d3 combined with lv5-fu) or other irinotecan-based...
17490736 - Igf-1r expression in localized cervical carcinoma patients treated by radiochemotherapy.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Gynecologic oncology     Volume:  96     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-01-21     Completed Date:  2005-03-03     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  323-9     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  adverse effects
Area Under Curve
Carboplatin / administration & dosage,  adverse effects
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Middle Aged
Ovarian Neoplasms / blood,  drug therapy*
Paclitaxel / administration & dosage,  adverse effects,  blood,  pharmacokinetics
Reg. No./Substance:
33069-62-4/Paclitaxel; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Electrosurgical bipolar vessel sealing for radical abdominal hysterectomy.
Next Document:  Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due ...